Xilio Therapeutics, Inc. XLO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 64.09M | 53.48M | 43.77M | 31.80M | 15.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.09M | 53.48M | 43.77M | 31.80M | 15.00M |
| Cost of Revenue | 10.80M | 11.57M | 0.00 | 5.54M | 1.98M |
| Gross Profit | 53.30M | 41.92M | 43.77M | 26.26M | 13.02M |
| SG&A Expenses | 28.63M | 28.12M | 29.71M | 28.83M | 28.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.46M | 95.73M | 85.75M | 75.58M | 71.65M |
| Operating Income | -31.37M | -42.24M | -41.98M | -43.78M | -56.65M |
| Income Before Tax | -21.83M | -31.30M | -35.04M | -58.49M | -56.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.83 | -31.30 | -35.04 | -58.49 | -56.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.83M | -31.30M | -35.04M | -58.49M | -56.22M |
| EBIT | -31.37M | -42.24M | -41.98M | -43.78M | -56.65M |
| EBITDA | -30.03M | -40.86M | -40.44M | -42.18M | -55.02M |
| EPS Basic | -4.73 | -8.04 | -8.88 | -14.00 | -12.69 |
| Normalized Basic EPS | -2.96 | -5.03 | -5.55 | -8.75 | -7.94 |
| EPS Diluted | -4.73 | -8.04 | -8.88 | -14.00 | -12.69 |
| Normalized Diluted EPS | -2.96 | -5.03 | -5.55 | -8.75 | -7.94 |
| Average Basic Shares Outstanding | 20.60M | 17.72M | 17.27M | 17.36M | 18.19M |
| Average Diluted Shares Outstanding | 20.60M | 17.72M | 17.27M | 17.36M | 18.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |